Archive for the ‘Pharmaceuticals’ Category

China To Build Uzbekistan Pharmaceutical Plants

Sunday, February 24th, 2013

Uzbekistan’s State Joint Stock Concern Uzfarmprom has signed deals with Chinese companies to build pharmaceutical enterprises in the Tashkent region worth a total $26.8 million, an Uzfarmprom representative said on Friday.

Huaian Rich International will build an ethanol manufacturing factory with capacity of 500,000 decaliters a year, as well as a bottle-cap making facility. Investment will total $12.8 million.

Kunmin Pharmaceutical will build a bronchopulmonary medication factory with capacity of 2 million doses, with investment of $14 million.

All the enterprises will be located in the Angren special industrial zone, set up last year, which has a special customs and tax regime.

Source: Eurasia Review

Uzbekistan plans to attract US$3.3bn of foreign investments in 2012

Friday, March 16th, 2012

Uzbekistan will continue active investment policy in 2012. It is planned to increase the volume of capital investments, directed to development of economy of the country. Their growth compared to 2011 will make up 9.3% and its share in GDP – 24.5%.

The volume of foreign investments and loans will grow by 16% and make up over US$3.3 billion, of which over US$2.3 billion or 70% will be foreign direct investments, which indicates interest and trust of foreign investors into economy of Uzbekistan.
In 2011, total volume of used investments in economy made up over US$10.8 billion, or grew by 11.2% year-on-year. At the same time, its share in GDP made up 24%, which is rated as above average level in line with international criteria.

The highest growth of investments was recorded in such sectors as automobile, chemistry, electrotechnical, textile, pharmaceutical, which produce ready products with high added cost.

Armenian drug manufacturers wish to enter Uzbek market

Wednesday, January 11th, 2012

Uzbekistan’s medical drug market has prospects for Armenian drug manufacturers. This is noted in the Pharmacy and Biotechnologies program document, which is a part of Armenia’s industrial policy geared toward export.

In 2010, Armenia exported US$ 8 million-worth pharmaceutical products, and the annual export growth is close to 20 percent. By 2015, export is expected to reach up to $20-25 million, and by 2020, $75-115 million.

Armenian-made drugs are currently exported to these countries: Georgia (38%), Russia (18%), Uzbekistan (13%), Belarus (6%), Ukraine (5%), and Qatar (4%).

Uzbekistan’s market is considered to be full of prospect because of its low development level and large population.


Uzbek-Indian joint venture Nova Pharm with estimated cost of $8 million opened

Thursday, September 8th, 2011

Termiz, Surkhandarya region commissioned the first line of Uzbek-Indian joint venture Nova Pharm. It will produce 14 kinds of medications.

Today the pharmaceutical industry of Uzbekistan is undergoing drastic changes. The influx of investment in this field ensures better quality of drugs produced and expands their range, upgrading of existing enterprises and construction of new plants. Currently there are 117 pharmaceutical companies in the country.

They produce more than 1,050 kinds of medications, some of which are exported abroad. The opening of Nova Pharm in Termiz with $8 million of estimated cost is a striking confirmation of dynamic development of the pharmaceutical industry.

$2 million were spent jointly with Indian partners on introduction of the first line of the modern enterprise. 50 new jobs were created here.

According to head of the regional health department Turakul Arzikulov, the first line of the new company, will greatly expand opportunities to ensure affordable and high quality medications for healthcare institutions in the country. After launching the second line of the enterprise and the production of high quality infusion and injection solutions, syrups and suspensions there will be no need of importing similar products from abroad.

It should be noted that construction of the second line of the joint venture is currently ongoing. With the company running at full capacity, 130 people will get jobs.

As director of Nova Pharm Satvinder Singh noted, favorable conditions created in Uzbekistan, ensure modern industrial complexes’ organization. The new joint venture will manufacture products to compete with foreign analogs. Forty percent of the drugs will be allocated to the domestic market, while sixty percent to be exported.


Uzbekistan seeks Pakistan investment in energy, textile sectors

Tuesday, August 23rd, 2011

Uzbekistan Ambassador Oybek Arif Usmanov offered Pakistan’s business community to invest in his country in various fields particularly in textiles, energy, pharmaceutical, leather to further enhance bilateral trade between both countries.

In meeting with President of Federation of Pakistan Chambers of Commerce & Industry FPCCI Haji Ghulam Ali, he said his country offered vast opportunities and liberal incentive packages for investment.

On behalf of Uzbekistans government, he invited a business delegation to visit Uzbekistan to utilize real trade, investment potential existing between two countries.

Pakistan delegation will meet Uzbek Prime Minister, Ministers, high government officials and business community members.

Senator Ghulam Ali thanked Uzbekistan for taking interest in promoting bilateral trade, enhance economic cooperation. He said FPCCI in cooperation with Trade Development Authority of Pakistan will constitute high powered delegation to visit Uzbekistan next month which will further strengthen Pak-Uzbek ties, significantly enhancing trade volume, finalize joint ventures for investment and MOU signed for promoting trade, investment in both countries.


Swiss firm to build insulin plant in Uzbekistan

Monday, May 30th, 2011

Uzbekistan will have its first insulin plant thanks to a Swiss firm which has begun construction in Tashkent.

Swiss company Ival AG will spend $150 million to construct the plant, which is scheduled to begin operations in 2014 while full-scale operations will not begin until 2015.

The 50-acre plant is being built in the Bostanlik section of Tashkent. Upon completion, the plant is expected to have the capacity to produce 500,000 pills and 100 million doses of infusion solutions.

It is estimated that 118,000 Uzbeks suffer from diabetes and need the insulin to maintain their sugar levels. While the Uzbek government provides the insulin to diabetes sufferers free of charge, it must import the substance. With this plant, Uzbekistan will no longer have to import the drug.

The Swiss-financed plant will export some of its output.

A German firm is only slated to finance another insulin-producing plant in Uzbekistan, the news agency noted. Diecon GmbH will bankroll a plant that will produce 25 million insulin doses in cartridges.

Source: Central Asia Newswire

Sharon Bio-Medicine Signs MoU To Form JV In Uzbekistan

Monday, February 28th, 2011

Sharon Bio-Medicine Ltd. said the company and The State – Joint Stock Concern “Uzpharmsanoat” of the Republic of Uzbekistan signed a memorandum of understanding or MoU to set up pharmaceutical plant in Navoi Free Industrial Economic Zone in Uzbekistan.

As per MoU, Sharon will provide necessary technology to new company to produce pharma products and make investment along with Govt. of Uzbekistan and a resident company/individual of Uzbekistan in the new company.

Uzbekistan government will assist Sharon to implement the project through preparation of documents, obtaining information from government and semi government bodies, participate in exhibitions and assist in financing the new company.

The company said the final detail agreement would be signed within three months from now and the new company would commence production in 15 months after signing the final detail agreement.

The new company will sell its products not only in Uzbekistan, but also in CIS countries. It can also sell its products to all over the world,a s there is no restriction on the new company.

Navoi Free Industrial Economic Zone is free from all taxes and Govt. of Uzbekistan has provided best of infrastructure facilities such as roads, railways, air services, water, electricity, communication etc.

At the BSE, Sharon Bio-Medicine closed Monday’s trading at Rs.147, up by 5.00 per cent from the previous close.

Source: RTTNews

Five-year CAGR of 10.4% (in dollars) projected for Uzbekistan’s pharmaceutical market by BMI

Tuesday, October 19th, 2010

Business Monitor International’s projection for Uzbekistan’s pharmaceutical market remains largely unchanged this quarter, with its five-year compound annual growth rate (CAGR) forecast at 10.37% in US dollar terms between 2009 and 2014, reaching a total value of 977.51 billion sum ($519 million) by the end of the forecast period.

Overall economic growth is expected to remain strong at between 7% and 8%.